NCT00471887已完成2 期
A Phase II, Open-Label, Single Arm Clinical Trial to Study the Mechanism of Action of CP-675,206 in Patients With In-Transit and Metastatic Melanoma Amenable to Repeated Outpatient Tumor Biopsies
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Change in Tumor Infiltration by Cluster of Differentiation 8 (CD8) Positive Cytotoxic T Lymphocytes
研究概览
简要总结
RATIONALE: Monoclonal antibodies, such as ticilimumab (CP-675,206), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PURPOSE: This phase II trial is studying how well ticilimumab (CP-675,206) works in treating patients with stage IIIC or stage IV melanoma.
详细描述
OBJECTIVES:
Primary
- Determine the change in melanoma intratumoral infiltrates by cluster of differentiation 8 (CD8 positive) cytotoxic T lymphocytes in patients with stage IIIC or IV melanoma treated with ticilimumab (CP-675,206).
Secondary
- Determine the effects of this drug on intratumoral immune effector cells and tumor cells in these patients.
- Determine the effects of this drug on circulating immune effector cells in these patients.
- Determine the gene expression profile of immune effector cells and tumor cells in regressing and nonregressing tumors in these patients.
- Bank plasma from peripheral blood obtained from patients with regressing and nonregressing tumors for future exploratory analysis of proteomic profile.
- Assess additional evidence of antitumor activity of this drug, as measured by best on-study response rate, in these patients.
- Characterize the safety profile and tolerability of this drug in these patients.
- Obtain pharmacokinetic data to be used in a future meta-analysis of this drug's pharmacokinetics.
- Determine whether the CTLA4 genotype influences the safety, immune response, and/or efficacy of this drug in these patients.
- Determine the relationships between clinical response (i.e., efficacy or toxicity) and tumor and/or blood ex vivo analysis in patients treated with this drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed melanoma that is surgically incurable and either:
- •Stage IIIc melanoma including locally relapsed, satellite, in-transit lesions or bulky draining lymph node metastasis.
- •Stage IV melanoma (M1a, M1b, M1c) with accessible lesions for biopsy.
- •At least 2 lesions amenable for outpatient biopsies
- •No restriction based on prior treatments
- •Disease progression after the last dose of prior therapy
- •A minimum of one measurable lesion defined as:
- •Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors
- •Skin lesion(s) selected as non-completely biopsied target lesions that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s).
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •Adequate bone marrow and hepatic function determined within 30 days prior to enrollment, defined as:
- •Absolute neutrophil count > 1.0 x 10^9 cells/L
- •Platelets > 90 x 10^9 /L
- •Hemoglobin > 9 g/L
- •Aspartate and alanine aminotransferases < 2.5 x upper limit of normal (ULN) (< 5 x ULN, if documented liver metastases are present)
- •Total bilirubin < 2 x ULN (except patients with documented Gilbert's syndrome)
- •Must be willing and able to provide writing informed consent.
- •Must be willing and able to accept at least two tumor biopsies.
- •Must be willing and able to accept at least two leukapheresis procedures.
排除标准
- •Received treatment for cancer, including immunotherapy, within one month prior to dosing.
- •Previous participation in Pfizer study A3671009: A Phase 3, Open Label, Randomized Comparative Study of CP-675,206 and Either Dacarbazine or Temozolomide in Patients with Advanced Melanoma
- •Eligible for enrollment to Pfizer A3671008: A Phase 2, Open Label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of CP-675,206 in Patients with Advanced Refractory and/or Relapsed Melanoma
- •History of significant evidence of risk for chronic inflammatory or autoimmune disease. Patents will be eligible if prior autoimmune disease of the hypophysis was treated locally or have resulted in fibrotic damage requiring thyroid hormone replacement. Vitiligo will not be a basis for exclusion.
- •History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis or any origin
- •Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 4 weeks prior to enrollment
- •Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
- •Clinically active brain metastases. Radiological documentation of absence of brain metastases at screening is required for all patients
- •Pregnancy or breast-feeding.
结局指标
主要结局
Change in Tumor Infiltration by Cluster of Differentiation 8 (CD8) Positive Cytotoxic T Lymphocytes
时间窗: pre treatment - post treatment at 24 months
Tumor infiltration of cluster of differentiation 4 and cluster of differentiation 8 (CD4+ and CD8+) cells (intratumoral and peritumoral) was assessed by immunohistochemistry of tumor tissue obtained through biopsy before and after administration of tremelimumab. Up to 10 randomly selected fields per sample were analyzed.
次要结局
- Overall Response (Complete or Partial Response) as Measured by RECIST Criteria(pre treatment - post treatment at 24 months)
- Change in Intratumoral Expression of the Proteins HLA-DR, CD45RO, Ki67 and FOXP3 and FOXP3"(pre treatment - post treatment at 24 months)
- Changes in the Protein Content in Peripheral Blood With an Increase in Proinflammatory Cytokines and Chemokines(pre treatment - post treatment at 24 months)
- Differences in Morphological and Gene Expression Profiling Studies in Peripheral Blood Mononuclear Cells(pre treatment - post treatment at 24 months)
- Overall Safety Profile as Measured by NCI CTCAE v2.0(pre treatment - post treatment at 24 months)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical CancerCervical CancerNCT01158248Medical University Innsbruck50
已完成
2 期
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell LymphomaLymphomaNCT00411086M.D. Anderson Cancer Center60
Unknown
2 期
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal CancerMetastatic CancerColorectal CancerNCT00438737European Organisation for Research and Treatment of Cancer - EORTC100
撤回
2 期
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV MelanomaMelanoma (Skin)NCT00357461Bristol-Myers Squibb
Unknown
2 期
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin LymphomaLymphomaNCT00896519French Innovative Leukemia Organisation30